Another Reorg for US FDA Drug Office: Dispute Resolution Program Moves Out

Executive Summary In another sign of the increasing influence of generics within FDA, CDER Director Woodcock moves the formal dispute resolution program out of the Office of New Drugs.

Executive Summary

In another sign of the increasing influence of generics within FDA, CDER Director Woodcock moves the formal dispute resolution program out of the Office of New Drugs.

FDA entrance sign 2016
Source: pink.pharmaintelligence.informa.com